Drug Development
With Lykos’ regulatory failure now squarely in the rearview mirror, Compass Pathways and Definium are leading what one analyst suspects will be “a very big year for psychedelics.”
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
This approval was based on the Phase III withdrawal study that showed clinically meaningful differences vs. placebo in change to the primary endpoint, Epworth Sleepiness Scale score.
COVID-19 probably can be eradicated globally, just like polio, according to research just published in BMJ Global Health. That assumes, however, that a high rate of vaccination occurs globally and that there is a quick response to emerging variants.
Aprea’s clinical trial is evaluating a combination of eprenetapopt with acalabrutinib or with venetoclax and rituximab.
The U.S. FDA greenlit the combination of Keytruda and Eisai’s Lemvima as a first-line treatment for adult patients with advanced renal cell carcinoma.
Citing a study from Johns Hopkins University, researchers found that immunocompromised people are 485 times more likely to end up in the hospital or die from COVID-19.
Trying to get clinical trials enrolled and completed creates a bottleneck that has hindered drug development for years. With a fresh $220 million in hand, Reify Health is looking to change that.
I-Mab announced positive interim data from its U.S. Phase II/III clinical trial of plonmarlimab for treatment of cytokine release syndrome in severe COVID-19.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Women who are pregnant are more vulnerable to developing severe illness after infection with SARS-Cov-2, the novel coronavirus that causes COVID-19.
Moderna will construct a manufacturing facility in Canada to provide direct access to mRNA vaccines for the COVID-19 pandemic and future viral threats and respiratory viruses.